#Liechtenstein #Vaduz #Implantica #GERD #RefluxStop

Implantica’s Third Quarter 2026 Investor Presentation

Implantica AG, a prominent player in the medtech industry, is gearing up for an important event as it invites investors to tune into its presentation for the third quarter of 2026, scheduled for November 19 at 15:00 CET. This presentation holds significant importance, particularly as it follows the earlier release of their interim report at 08:00 CET on the same day.

Details of the Presentation

The event will be conducted in English and will be accessible via a webcast. Investors interested in participating can find the link here to join the webcast. Alternatively, for those wishing to be part of the teleconference, registration is available, which will provide the necessary dial-in number and conference ID. Interested parties can register through this link.

Top executives will take the stage during the presentation, including CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson. Their insights and updates will be pivotal for investors keen on understanding the company's trajectory and operational status in the ever-evolving medtech landscape.

A Closer Look at Implantica

Implantica is distinguished for its commitment to innovative implantable technologies aimed at advancing patient care and outcomes. Its flagship product, the RefluxStop®, has garnered attention for its role in treating gastroesophageal reflux disease (GERD), a condition that greatly affects quality of life for many individuals. The RefluxStop® device is not only FDA approved but also marked with the CE certification, signifying its adherence to rigorous medical standards.

The unique approach of the RefluxStop® is what sets it apart from traditional anti-reflux surgeries, which typically involve wrapping the esophagus—a method often linked to numerous side effects. Instead, RefluxStop® focuses on restoring functioning to the lower esophageal sphincter without exerting external pressure or wrapping, thus minimizing potential complications. Its design aims to ensure that the physiological mechanisms of the gastroesophageal junction operate normally, which is key to preventing both acid and non-acid reflux.

Innovation and Research at the Forefront

In addition to the RefluxStop®, Implantica boasts a robust pipeline filled with patent-protected innovations which seek to address various medical challenges. This includes a state-of-the-art eHealth platform that facilitates communication, remote monitoring, and control of implants, as well as a wireless energizing platform to power devices through the skin without invasive procedures. Such innovations hold promise not only for improved patient experiences but also for cost-effectiveness in healthcare provision.

The long-term outcomes related to the RefluxStop® treatment have been positively reviewed in various scientific journals, reinforcing its efficacy and safety. Clinical data suggests that a significant number of patients who underwent treatment have experienced meaningful relief with an acceptable risk profile when adhering to the prescribed use.

Join the Presentation

The forthcoming investor presentation by Implantica is more than just a corporate update; it reflects the company's ongoing dedication to innovative medical solutions and improving patient lives. Investors and stakeholders are encouraged to participate to gain valuable insights into the company’s performance and future directions.

For further information or inquiries, stakeholders can reach out to Nicole Pehrsson, Head of Investor Relations, whose contact details are provided in the corporate announcement.

With the date marked on calendars and anticipation building, the upcoming presentation stands as a significant highlight for Implantica and its stakeholders alike.